toripalimab
Shanghai Junshi Bioscience,coherus
['toripalimab', 'sclc', 'lcsm,(-blcsm)', 'nsclc', 'choice-01']
choice-01: toripalimab + chemo in 1l for patients without driver mutations show benefit in os both on squamous and non-squamous nsclc. no benefit for pd-l1 50%. nothing really new on the horizon. #asco23 #lcsm 
Husband, Father. Medical Oncologist and Researcher focused in Thoracic Oncology.  Views are my own. Member of @latenightonc - the best podcast in oncology!